Lexicon Pharmaceuticals Operating Income 2006-2021 | LXRX

Lexicon Pharmaceuticals operating income from 2006 to 2021. Operating income can be defined as income after operating expenses have been deducted and before interest payments and taxes have been deducted.
Lexicon Pharmaceuticals Annual Operating Income
(Millions of US $)
2020 $-48
2019 $141
2018 $-103
2017 $-131
2016 $-127
2015 $1
2014 $-100
2013 $-102
2012 $-108
2011 $-114
2010 $-96
2009 $-90
2008 $-97
2007 $-75
2006 $-55
2005 $-36
Lexicon Pharmaceuticals Quarterly Operating Income
(Millions of US $)
2021-06-30 $-18
2021-03-31 $-21
2020-12-31 $-7
2020-09-30 $87
2020-06-30 $-65
2020-03-31 $-62
2019-12-31 $-47
2019-09-30 $225
2019-06-30 $-19
2019-03-31 $-17
2018-12-31 $-12
2018-09-30 $-23
2018-06-30 $-30
2018-03-31 $-38
2017-12-31 $-25
2017-09-30 $-30
2017-06-30 $-34
2017-03-31 $-42
2016-12-31 $-21
2016-09-30 $-35
2016-06-30 $-37
2016-03-31 $-34
2015-12-31 $88
2015-09-30 $-34
2015-06-30 $-27
2015-03-31 $-27
2014-12-31 $-3
2014-09-30 $-40
2014-06-30 $-26
2014-03-31 $-30
2013-12-31 $-17
2013-09-30 $-31
2013-06-30 $-29
2013-03-31 $-26
2012-12-31 $-24
2012-09-30 $-29
2012-06-30 $-25
2012-03-31 $-29
2011-12-31 $-33
2011-09-30 $-26
2011-06-30 $-26
2011-03-31 $-29
2010-12-31 $-22
2010-09-30 $-24
2010-06-30 $-24
2010-03-31 $-25
2009-12-31 $-22
2009-09-30 $-22
2009-06-30 $-23
2009-03-31 $-24
2008-12-31 $-21
2008-09-30 $-25
2008-06-30 $-26
2008-03-31 $-24
2007-12-31 $-18
2007-09-30 $-19
2007-06-30 $-18
2007-03-31 $-19
2006-12-31 $-15
2006-09-30 $-13
2006-06-30 $-17
2006-03-31 $-11
2005-12-31 $6
2005-09-30 $-14
2005-06-30 $-15
2005-03-31 $-13
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.714B $0.024B
Lexicon Genetics Incorporated is a leader in defining the functions of genes for drug discovery using large-scale knockout mouse technology. Lexicon has invented high-throughput gene trapping technology to discover thousands of genes and expand its OmniBank library of tens of thousands of mouse clones. The Company uses an integrated platform of functional genomictechnologies to accelerate large-scale analysis of mammalian gene function for drug discovery.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $133.838B 8.91
Bio-Rad Laboratories (BIO.B) United States $23.483B 50.05
QIAGEN (QGEN) Netherlands $12.341B 20.90
Biohaven Pharmaceutical Holding (BHVN) United States $8.723B 0.00
Emergent Biosolutions (EBS) United States $2.813B 6.79
Arcus Biosciences (RCUS) United States $2.568B 0.00
Myovant Sciences (MYOV) United Kingdom $2.170B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.949B 0.00
Zymeworks (ZYME) Canada $1.323B 0.00
Ambrx Biopharma (AMAM) United States $0.509B 0.00
SQZ Biotechnologies (SQZ) United States $0.428B 0.00
Enzo Biochem (ENZ) United States $0.174B 51.29